• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Warnex's Bioanalytical Services Division Acquires Two State-of-the-Art TSQ Vantage Mass Spectrometers

Posted on: Thursday, 16 October 2008, 12:00 CDT

Warnex Inc. (TSX: WNX) announced today that its Bioanalytical Services division has acquired two state-of-the-art TSQ Vantage mass spectrometers from Thermo Fisher Scientific Inc.

"We are pleased to be the first CRO in Canada to acquire the new TSQ Vantage system," said Mark Busgang, President and CEO of Warnex. "Warnex strives to be at the forefront of technology in order to offer our customers the most advanced services available. The increased sensitivity of this new generation of systems will allow us to detect our customers' compounds at very low quantitation levels with great precision."

The TSQ Vantage system delivers up to 10 times more sensitivity than any other triple quadrupole instrument on the market and does not produce a commensurate increase in noise. New technical breakthroughs have given the TSQ Vantage unmatched signal-to-noise performance, providing better reproducibility and precision in the quantitative analysis of small molecules, biomolecules and peptides.

Warnex Bioanalytical Services offers a range of services to the pharmaceutical and biotechnology industries, specializing in bioavailability and bioequivalence studies. A scientific team of specialists in research and development, method development and validation, production, and quality assurance, supports companies in their drug development programs by carrying out analyses generated throughout the program, beginning with pre-clinical studies and proceeding with evaluation of the drug in human clinical trials. Support to the generic drug industry is provided by analyzing physiological fluid samples obtained from clinical studies in humans to determine whether the new formulations are bioequivalent to the marketed product.

About Warnex

Warnex (www.warnex.ca) is a life sciences company devoted to protecting public health by providing laboratory services to the pharmaceutical and healthcare sectors. Warnex's analytical services division provides pharmaceutical and biotechnology companies with a variety of quality control services, including traditional chemistry, chromatography, microbiology, method development and validation, and stability studies. Warnex's bioanalytical services division specializes in bioequivalence and bioavailability studies for clinical trials. Warnex's medical laboratories division focuses on genetic and biochemical testing for the healthcare industry and has extensive expertise in genetic testing for human identification, molecular diagnostics, and pharmacogenetics.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For information identifying known risks and uncertainties, relating to financial resources, government regulations, laboratory facilities, suppliers, employees, key customers and business partners, foreign currency risk, credit risk, liquidity risk, volatility of share price, and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Warnex's most recent Management's Discussion and Analysis, which can be found at www.sedar.com. Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.

 Contacts: Warnex Inc. Mark J. Busgang President & CEO 450-663-6724 x 310 mbusgang@warnex.ca  Warnex Inc. Catherine Sartoros Communications Specialist 450-663-6724 x 277 csartoros@warnex.ca

SOURCE: Warnex Inc.

Source: MARKET WIRE

More News in this Category